{"prompt": "['2016N277425_0', 'CONFIDENTIAL', '2018N377698_00', '201749', 'INVESTIGATOR PROTOCOL AGREEMENT PAGE', 'For protocol number 201749', 'I confirm agreement to conduct the study in compliance with the protocol, as amended by', 'this protocol amendment.', 'I acknowledge that I am responsible for overall study conduct. I agree to personally', 'conduct or supervise the described study.', 'I agree to ensure that all associates, colleagues and employees assisting in the conduct of', 'the study are informed about their obligations. Mechanisms are in place to ensure that site', 'staff receives the appropriate information throughout the study.', 'Investigator Name:', 'Investigator Address:', 'Investigator Phone Number:', 'Investigator Signature', 'Date', '6']['2016N277425_0', 'CONFIDENTIAL', '2018N377698_00', '201749', 'TABLE OF CONTENTS', 'PAGE', '1. PROTOCOL SYNOPSIS FOR STUDY 201749', '10', '2. INTRODUCTION', '15', '2.1.', 'Study Rationale', '15', '2.2.', 'Brief Background', '15', '3.', 'OBJECTIVE(S) AND ENDPOINT(S)', '16', '4.', 'STUDY DESIGN', '18', '4.1.', 'Overall Design', '18', '4.2.', 'Treatment Arms and Duration', '20', '4.3.', 'Type and Number of Subjects', '21', '4.4.', 'Design Justification', '21', '4.5.', 'Dose Justification', '21', '4.6.', 'Benefit: Risk Assessment', '21', '4.6.1.', 'Risk Assessment', '22', '4.6.2.', 'Benefit Assessment', '25', '4.6.3.', 'Overall Benefit: Risk Conclusion', '25', '5. SELECTION OF STUDY POPULATION AND WITHDRAWAL CRITERIA', '25', '5.1.', 'Inclusion Criteria', '25', '5.2.', 'Exclusion Criteria', '27', '5.3.', 'Randomization Criteria', '30', '5.4.', 'Screening/Baseline/Run-in Failures', '30', '5.5.', 'Withdrawal/Stopping Criteria', '31', '5.5.1.', 'Withdrawal from the Study', '31', '5.5.2.', 'Reason for Study Withdrawal', '32', '5.5.3.', 'Liver Chemistry Stopping Criteria', '32', '5.5.3.1.', 'Study Treatment Restart or Rechallenge', '33', '5.6.', 'Follow-up contact', '33', '5.7.', 'Subject and Study Completion', '34', '6.', 'STUDY TREATMENT', '34', '6.1.', 'Investigational Product and Other Study Treatment', '34', '6.2.', 'Medical Devices', '36', '6.3.', 'Treatment Assignment', '36', '6.4.', 'Planned Dose Adjustments', '37', '6.5.', 'Blinding', '37', '6.6.', 'Packaging and Labeling', '38', '6.7.', 'Preparation/Handling/Storage/Accountability', '38', '6.7.1.', 'Study Treatment Return', '39', '6.8.', 'Compliance with Study Treatment Administration', '39', '6.9.', 'Treatment of Study Treatment Overdose', '39', '6.10.', 'Treatment after the End of the Study', '40', '6.11.', 'Concomitant Medications and Non-Drug Therapies', '40', '6.11.1. Permitted Medications and Non-Drug Therapies', '40', '6.11.2. Prohibited Medications and Non-Drug Therapies', '41', '7.', 'STUDY ASSESSMENTS AND PROCEDURES', '42', '7']['2016N277425_0', 'CONFIDENTIAL', '2018N377698_00', '201749', '7.1.', 'Time and Events Table', '43', '7.2.', 'Screening and Critical Baseline Assessments', '46', '7.2.1.', 'Pre-screening Visit', '46', '7.2.2.', 'Critical procedures performed at Screening (Visit 1)', '46', '7.2.2.1. Albuterol/Salbutamol Reversibility Assessment', '47', '7.2.3.', 'Critical procedures performed at first treatment Visit', '(Baseline V2)', '47', '7.3.', 'Efficacy Assessments', '48', '7.3.1.', 'HRQoL assessments: Completion of PRO questionnaires', 'in the Electronic Diary', '48', '7.3.1.1.', 'Self Administered Computerised Baseline', 'Dyspnea Index/Transitional Dyspnea Index', '(SAC BDI/TDI)', '48', '7.3.1.2.', 'SGRQ-C', '49', '7.3.1.3.', 'COPD Assessment Test (CAT)', '49', '7.3.1.4.', 'EXACT and the Evaluating Respiratory', 'Symptoms- COPD (E-RS: COPD)', '50', '7.3.1.5.', 'Subject Global Rating of COPD Severity and', 'Global Rating of Change in COPD', '50', '7.3.2.', 'Spirometry', '50', '7.3.3.', 'Inspiratory capacity (IC)', '51', '7.3.4.', 'COPD Exacerbation', '52', '7.3.5.', 'Clinically important deterioration (CID)', '52', '7.3.6.', 'Rescue albuterl/salbutamol use', '53', '7.3.7.', 'Physical activity monitor (study subset)', '53', '7.4.', 'Safety', '53', '7.4.1.', 'Adverse Events (AE) and Serious Adverse Events (SAEs)', '53', '7.4.1.1.', 'Time period and Frequency for collecting AE', 'and SAE information', '54', '7.4.1.2.', 'Method of Detecting AEs and SAEs', '54', '7.4.1.3.', 'Follow-up of AEs and SAEs', '54', '7.4.1.4.', 'Pneumonia Events', '55', '7.4.1.5.', 'Cardiovascular and Death Events', '55', '7.4.1.6.', 'Disease-Related Events and/or Disease-', 'Related Outcomes Not Qualifying as SAEs', '55', '7.4.1.7.', 'Regulatory Reporting Requirements for SAEs', '55', '7.4.2.', 'Pregnancy', '56', '7.4.3.', 'Medical Device Incidents (Including Malfunctions)', '56', '7.4.4.', 'Electrocardiogram (ECG)', '56', '7.5.', 'Genetics', '56', '8.', 'DATA MANAGEMENT', '56', '9.', 'STATISTICAL CONSIDERATIONS AND DATA ANALYSES', '57', '9.1.', 'Hypotheses', '57', '9.2.', 'Sample Size Considerations', '57', '9.2.1.', 'Sample Size Assumptions', '58', '9.2.2.', 'Sample Size Sensitivity', '58', '9.2.3.', 'Sample Size Re-estimation or Adjustment', '58', '9.3.', 'Data Analysis Considerations', '58', '9.3.1.', 'Analysis Populations', '58', '9.3.2.', 'Interim Analysis', '59', '8']\n\n###\n\n", "completion": "END"}